All Stories

  1. Phosphatidylinositol 4,5-Bisphosphate-Dependent Oligomerization of the Pseudomonas aeruginosa Cytotoxin ExoU

    Article • Infection and Immunity, October 2017, ASM Journals

    Dr Alan R Hauser

  2. Impact of Type III Secretion Effectors and of Phenoxyacetamide Inhibitors of Type III Secretion on Abscess Formation in a Mouse Model of Pseudomonas aeruginosa Infection

    Article • Antimicrobial Agents and Chemotherapy, August 2017, ASM Journals

    Dr Alan R Hauser

  3. Influence of ACB complex genospecies on clinical outcomes in a U.S. hospital with high rates of multidrug resistance

    Article • Journal of Infection, February 2015, Elsevier

    Dr Alan R Hauser

  4. Pseudomonas Activation of the Inflammasome

    Article • December 2014, Springer Science + Business Media

    Dr Alan R Hauser

  5. A Novel Phosphatidylinositol 4,5-Bisphosphate Binding Domain Mediates Plasma Membrane Localization of ExoU and Other Patatin-like Phospholipases

    Article • Journal of Biological Chemistry, December 2014, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Alan R Hauser

  6. The Pseudomonas aeruginosa Type III Translocon Is Required for Biofilm Formation at the Epithelial Barrier

    Article • PLoS Pathogens, November 2014, PLOS

    Dr Alan R Hauser

  7. The ADP-Ribosyltransferase Domain of the Effector Protein ExoS Inhibits Phagocytosis of Pseudomonas aeruginosa during Pneumonia

    Article • mBio, June 2014, ASM Journals

    Dr Alan R Hauser

  8. Genome-Wide Identification of Acinetobacter baumannii Genes Necessary for Persistence in the Lung

    Article • mBio, June 2014, ASM Journals

    Mark Mandel, Dr Alan R Hauser

  9. Different paths to pathogenesis

    Article • Trends in Microbiology, April 2014, Elsevier

    Dr Alan R Hauser

  10. Pseudomonas aeruginosa Virulence and Antimicrobial Resistance

    Article • Critical Care Medicine, January 2014, Wolters Kluwer Health

    Dr Alan R Hauser

  11. Characterization of the core and accessory genomes of Pseudomonas aeruginosa using bioinformatic tools Spine and AGEnt

    Article • BMC Genomics, January 2014, Springer Science + Business Media

    Dr Alan R Hauser

  12. Hypercapnia Impairs Lung Neutrophil Function and Increases Mortality in MurinePseudomonasPneumonia

    Article • American Journal of Respiratory Cell and Molecular Biology, November 2013, American Thoracic Society

    Dr Alan R Hauser, Dr. Peter H. Sporn

  13. Phosphatidylinositol 4,5-Bisphosphate Is a Novel Coactivator of the Pseudomonas aeruginosa Cytotoxin ExoU

    Article • Infection and Immunity, May 2013, ASM Journals

    Dr Alan R Hauser

  14. Type III Secretion of ExoU Is Critical during Early Pseudomonas aeruginosa Pneumonia

    Article • mBio, March 2013, ASM Journals

    Dr Alan R Hauser

  15. Structure of the Type III Secretion Effector Protein ExoU in Complex with Its Chaperone SpcU

    Article • PLoS ONE, November 2012, PLOS

    Dr Alan R Hauser

  16. Ventilator-associated pneumonia caused by Pseudomonas aeruginosa

    Article • Critical Care Medicine, August 2012, Wolters Kluwer Health

    Dr Alan R Hauser

  17. Clinical outcomes of type III Pseudomonas aeruginosa bacteremia*

    Article • Critical Care Medicine, April 2012, Wolters Kluwer Health

    Dr Alan R Hauser

  18. Pseudomonas aeruginosa: So many virulence factors, so little time*

    Article • Critical Care Medicine, September 2011, Wolters Kluwer Health

    Dr Alan R Hauser

  19. The Role Of Mexxy Efflux Pump Expression In The Development Of Aminoglycoside Resistance In P. Aeruginosa Over Time In Patients With Cystic Fibrosis

    Article • May 2011, American Thoracic Society

    Dr Alan R Hauser

  20. Hypercapnia Impairs Lung Bacterial Clearance And Increases Mortality In Murine Pseudomonas Pneumonia

    Article • May 2010, American Thoracic Society

    Dr Alan R Hauser, Dr. Peter H. Sporn

  21. Electrostatic interactions play a minor role in the binding of ExoS to 14-3-3 proteins

    Article • Biochemical Journal, April 2010, Portland Press Ltd.

    Dr Alan R Hauser

  22. The type III secretion system of Pseudomonas aeruginosa: infection by injection

    Article • Nature Reviews Microbiology, September 2009, Springer Science + Business Media

    Dr Alan R Hauser

  23. Morbidity associated with Pseudomonas aeruginosa bloodstream infections

    Article • Diagnostic Microbiology and Infectious Disease, July 2009, Elsevier

    Marc Scheetz, Dr Alan R Hauser, Dr Marc H. Scheetz

  24. Pseudomonas aeruginosa virulence and therapy: Evolving translational strategies*

    Article • Critical Care Medicine, May 2009, Wolters Kluwer Health

    Dr Alan R Hauser

  25. Genomic islands ofPseudomonas aeruginosa

    Article • FEMS Microbiology Letters, January 2009, Oxford University Press (OUP)

    Dr Alan R Hauser

  26. Evolution of Pseudomonas aeruginosa type III secretion in cystic fibrosis: a paradigm of chronic infection

    Article • Translational Research, December 2008, Elsevier

    Dr Alan R Hauser

  27. The biofilm life cycle and virulence of Pseudomonas aeruginosa are dependent on a filamentous prophage

    Article • The ISME Journal, November 2008, Oxford University Press (OUP)

    Dr Alan R Hauser, Professor Diane McDougald, A/Prof Diane McDougald

  28. Pseudomonas aeruginosa

    Article • American Review of Respiratory Disease, September 2008, American Thoracic Society

    Dr Alan R Hauser

  29. Pseudomonas aeruginosa uses type III secretion system to kill biofilm-associated amoebae

    Article • The ISME Journal, May 2008, Oxford University Press (OUP)

    Dr Alan R Hauser

  30. Antibiotics Basics For Clinicians: Choosing the Right Antibacterial Agent Alan R. Hauser Philadelphia: Lippincott Williams & Wilkins, 2007 320 pp., illustrated. $32.95

    Article • Clinical Infectious Diseases, February 2008, Oxford University Press (OUP)

    Dr Alan R Hauser

  31. PSEUDOMONAS AERUGINOSA INDUCES LOCALIZED IMMUNOSUPPRESSION DURING PNEUMONIA

    Article • CHEST Journal, October 2007, Elsevier

    Dr Alan R Hauser

  32. Phosphorylation-independent interaction between 14-3-3 and exoenzyme S: from structure to pathogenesis

    Article • The EMBO Journal, January 2007, Springer Science + Business Media

    Dr Alan R Hauser

  33. HETEROGENEITY IN ANTIBIOTIC SUSCEPTIBILITIES OF PSEUDOMONAS AERUGINOSA RESPIRATORY ISOLATES FROM INDIVIDUALS WITH CYSTIC FIBROSIS

    Article • CHEST Journal, October 2006, Elsevier

    Dr Alan R Hauser

  34. SeverePseudomonas aeruginosainfections

    Article • Postgraduate Medicine, January 2005, Taylor & Francis

    Dr Alan R Hauser

  35. Secretion of the Toxin ExoU Is a Marker for Highly Virulent Pseudomonas aeruginosa Isolates Obtained from Patients with Hospital‐Acquired Pneumonia

    Article • The Journal of Infectious Diseases, December 2003, Oxford University Press (OUP)

    Dr Alan R Hauser

  36. Severe Infections Caused by Pseudomonas Aeruginosa

    Article • January 2003

    Dr Alan R Hauser

  37. Subinhibitory Bismuth-Thiols Reduce Virulence ofPseudomonas aeruginosa

    Article • American Journal of Respiratory Cell and Molecular Biology, June 2002, American Thoracic Society

    Dr Alan R Hauser

  38. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa

    Article • Critical Care Medicine, March 2002, Wolters Kluwer Health

    Dr Alan R Hauser

  39. Another toxic shock syndrome

    Article • Postgraduate Medicine, December 1998, Taylor & Francis

    Dr Alan R Hauser

  40. PepA, a secreted protein of Pseudomonas aeruginosa, is necessary for cytotoxicity and virulence

    Article • Molecular Microbiology, February 1998, Wiley

    Dr Alan R Hauser

  41. Identification of Pseudomonas aeruginosa genes required for epithelial cell injury

    Article • Molecular Microbiology, June 1997, Wiley

    Dr Alan R Hauser

  42. Familial male breast cancer

    Article • American Journal of Medical Genetics, December 1992, Wiley

    Dr Alan R Hauser